Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 19/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 10/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22860672 | 0.88 | MAPT (0.79) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL9618122 | 0.77 | MAPT (0.63) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL23010594 | 0.72 | MAPT (0.58) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL8919052 | 0.72 | MAPT (0.58) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL4539425 | 0.70 | MAPT (0.54) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL10890683 | 0.69 | MAPT (0.54) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL22860673 | 0.69 | MAPT (0.52) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL20784531 | 0.67 | MAPT (0.53) | MAPTTHRBUSP2POLB | |
| SCHEMBL13292998 | 0.67 | MEN1 (0.57) | MAPTTHRBUSP2TP53LMNA | |
| SCHEMBL7923952 | 0.67 | HTR1A (0.58) | MAPTTHRBUSP2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220016-B2 | Methods and materials for assessing chemotherapy responsiveness and treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220016-B2 | Methods and materials for assessing chemotherapy responsiveness and treating cancer | PKD2, USP2, BRCA1 | MAPT 4230/4885THRB 3869/4885USP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.